Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this ...

Clinical-stage biotech Tryptamine Therapeutics (ASX:TYP) has successfully and safely completed obese-subject dosing in its ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025Scott Wolchko To Retire as President and CEO after 10 years of Leadership in ...

Alumis Inc. (NASDAQ: ALMS) recently disclosed revisions to its estimates for primary completion and study completion dates ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

Request To Download Sample of This Strategic Report @ R&D budget for the development of drug has increased the demand of global preclinical contract organization (CRO). According to Servier Research ...